We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Resources

Posters & Publications

18 Jun 2021
KY1044-CT01: Phase I/II study of anti-ICOS antibody
At the June 2021 American Society of Clinical Oncology (ASCO) Kymab presented a poster on the ongoing phase 1/2 open-label study of KY1044, a fully human anti-ICOS IgG1 antibody with dual mechanism of action, as single agent and in combination with atezolizumab in adult patients with selected advanced malignancies.
18 Jun 2021
KY1044 : targets the ICOS pathways inducing intratumoral T-reg depletion and agonism of effector T cells
At the June 2021 American Society of Clinical Oncology (ASCO) Kymab presented a poster on how KY1044 targets the ICOS pathways inducing intratumoral T-reg depletion and agonism of effector T cells using preliminary pharmacodynamic markers from the ongoing Phase 1/2 clinical trial.
26 Sep 2020
Exploiting KY1044 to restore an antitumour immune response
Kymab peer-reviewed research published on 30 September 2020 in Cancer Immunology Research (a journal of the American Association for Cancer Research) demonstrates that KY1044, Kymab’s fully human anti-ICOS antibody, increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression.
26 Sep 2020
Monoclonal antibodies and antimicrobial resistance
In this September 2020 Lancet Microbe commentary, Kymab scientists and colleagues explore how monoclonal antibodies could support efforts to prevent or treat antimicrobial resistant bacteria infections in intensive care settings.
26 Jun 2020
KY1044: ICOS content and patient survival
At the American Association for Cancer Research (AACR) Virtual Annual Meeting in June 2020, Kymab researchers presented data using their anti ICOS antibody that suggests that high content of Tregs expressing ICOS in the tumour microenvironment is associated with poorer survival in patients with hepatocellular carcinoma.
26 Jun 2020
KY1043 delivers potent anti-tumour activity in vivo
At the American Association for Cancer Research (AACR) Virtual Annual Meeting in June 2020, Kymab researchers presented data showing that KY1043, a novel CD25-directed PD-L1 IL-2 immunocytokine, provides targeted immune checkpoint inhibition coupled with dose-dependent anti-tumour activity.
26 May 2020
KY1070: anti-BMP6 antibody reduces EPO need in anaemia model
Research published in Blood on 21 May 2020 demonstrates that KY1070, Kymab’s fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the Anaemia of Chronic Disease. Effects are seen - either as monotherapy or in combination with Darbepoetin alfa - on iron metabolism and anaemia resolution.
26 Dec 2019
KY1049: the first fully human Factor VIII-mimetic bispecific antibody
At the American Society of Hematology 61st Annual Meeting on December 8, 2019 in Orlando, Florida, Kymab Senior Research Scientist Dr John Blackwood, presented data showing that KY1049, a Factor VIII mimetic bispecific antibody, functionally rescues Factor VIII deficiency ex vivo.
26 Dec 2019
KY1066: anti-matriptase-2 antibody and β thalassemia
At the American Society of Hematology 61st Annual Meeting on December 9, 2019 in Orlando, Florida, Kymab Research Scientist Dr Matthew Wake presented new findings on KY1066, a first-in-class, fully human antibody targeting the enzymatic activity of matriptase-2 for the treatment of iron overload diseases, such as β thalassemia.
26 Nov 2019
Kymab antibody for Pulmonary Arterial Hypertension
Research published on Friday 15 November 2019 in Nature Communications from the University of Sheffield’s Department of Infection, Immunity and Cardiovascular Disease shows that treatment with a specific Kymab antibody can potentially reverse the process behind the development of Pulmonary Arterial Hypertension or PAH. The authors state that targeting "with a therapeutic antibody is a potential treatment strategy in PAH”.
26 Nov 2019
KY1043: immunocytokine stimulates potent anti-tumour responses in vivo
At the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland on Friday 8 November, 2019, Kymab Senior Research Scientist Cassie Van Krinks presents data showing that targeting PD-L1 and the IL-2 receptor with KY1043 is a valid approach for inducing a strong anti-tumor immune response.
26 Oct 2019
KY1049: a fully human Factor VIII bispecific antibody at ECTH19
At the European Congress on Thrombosis and Haemostasis (ECTH) in Glasgow, UK on October 3, 2019, Kymab Senior Research Scientist, Dr John Blackwood, outlined the development and preclinical evaluation of KY1049, the Company’s fully human Factor VIII (FVIII)-mimetic bispecific antibody.
26 Sep 2019
KY1044: Expanding data set continues to provide evidence for a dual mechanism-of-action
At the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON) in Paris, September 27, 2019, Dr Richard Sainson, Kymab’s Senior Director, Translational Medicine, presented positive new findings for Kymab’s KY1044 Anti-ICOS Programme.
26 Sep 2019
Anti-ICOS KY1044 antibody induces tumour regression; bioRxiv preprint
Kymab researchers have deposited a preprint publication at Biorxiv describing KY1044 preclinical data and entitled "A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression". The expanding data set strengthens evidence for a dual mechanism of action of KY1044: the study shows that a targeted approach can be used to exploit differential ICOS expression patterns, allowing depletion of ICOShigh TReg cells, agonism of ICOSlow TEff cells and an overall increase in the TEff:TReg ratio in the tumour microenvironment. This shift in the immune contexture resulted in a strong and long lasting anti-tumour response.
26 Jun 2019
KY1005: Phase 1 safety, pharmacokinetics and TDAR
At the 24th World Congress of Dermatology in Milan, June 10-15, 2019, Kymab’s Senior Medical Director Dr Porter-Brown presented data showing that Kymab’s novel anti-OX40L monoclonal antibody, with potential in atopic dermatitis, demonstrates acceptable safety and tolerability profiles. The results support development of KY1005 in immune-mediated diseases, such as AD, and a phase 2a study is under way.
26 Jun 2019
KY1049: Factor VIII mimetic bispecific antibody
At the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 15, Kymab will deliver an oral presentation on pre-clinical evaluation of KY1049, Kymab’s proprietary FVIII mimetic antibody Abstract: S851
26 Jun 2019
Development of a fully human FVIII mimetic bispecific antibody
At the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 14, Kymab will present a poster on development of KY1049 using Kymab’s proprietary Intelliselect Bispecific Platform which can efficiently generate diverse and extensive panels of fully human, common light chain bispecific antibodies. Abstract: PF338 at https://library.ehaweb.org/.
26 Jun 2019
KY1044-CT01: Phase I/II study of anti-ICOS antibody
At the June 2019 American Society of Clinical Oncology (ASCO) Kymab presented a poster and had an abstract on an ongoing first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.
16 Jun 2019
KY1005 suppresses response to KLH in healthy volunteers
At the 24th World Congress of Dermatology in Milan, June 10-15, 2019, Kymab’s Senior Medical Director Dr Porter-Brown presented data showing that Kymab’s OX40L-blocking monoclonal antibody KY1005 strongly suppresses the delayed-type hypersensitivity skin response to KLH in healthy volunteers. A phase 2a study in moderate to severe atopic dermatitis is under way.
26 Apr 2019
Cell lines to screen anti-cancer antibodies
At the April 2019 European Laboratory Research & Innovation Group (ELRIG) – Research & Innovations, Kymab presented data on the development of innovative assays for testing of our therapeutic antibodies, including work conducted using macrophage-like cell lines for high-throughput screening of molecules able to modulate macrophage function.
26 Apr 2019
T-cell imaging for antibody evaluation
At the April 2019 European Laboratory Research & Innovation Group (ELRIG) – Research & Innovations, Kymab presented results describing the development of an imaging-based T-cell infiltration assay, a model that can be multiplexed with tumour killing and activation as readouts and has the potential to be used to screen drug candidates while enabling a better understanding of the complex biology of the tumour microenvironment.
26 Mar 2017
Screening for anti-human PD-L1 antibodies
At the 2017 British Society for Immunology Congress, Kymab's team describe a cell-based, in vitro screening cascade to characterise anti-human PD-L 1 antibodies, identifying a lead clone, KY1003, that has the attributes of a clinically relevant PD-L1 antibody
26 Mar 2017
Modelling T-cells in tumour microenvironments
The Kymab team developed a "tumour-educated" T-cell killing assay for predictive in vitro assessment of anti-PD-L1 antibodies: data presented at the 2017 British Society for Immunology Congress shows how KY1003 can revert T-cell exhaustion in in vitro models.
26 Mar 2014
Humanization of mouse immunoglobulin genes
Kymab published a report in Nature Biotechnology in March 2014 showing the engineering of mice with the full set of human antibody genes. These mice can produce an enormous range of human antibodies, which can be developed as potent drugs to treat a variety of human diseases such as cancer, autoimmune and infectious diseases.

Sanofi and Kymab have joined forces to bring new medicines to patients.

Read the press release